Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment

Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment · Investor's Business Daily
ALLISON GATLIN and ALAN R. ELLIOTT
2 min read

In This Article:

Nurix posted a "clear win" in leukemia treatment on Monday, but the biotech stock gave back some of its gains.

Recommended Stories